Cargando…

A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes

Dosing guidelines for patients with type 1 diabetes using continuous subcutaneous insulin infusion (CSII), which are historically based on clinical experience and retrospective studies of patients consuming an American diet, recommend that basal insulin should represent approximately 50 % of the tot...

Descripción completa

Detalles Bibliográficos
Autores principales:	King, Allen B., Kuroda, Akio, Matsuhisa, Munehide, Hobbs, Todd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2016
Materias:	Treatment of Type 1 Diabetes (M Pietropaolo, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960276/ https://www.ncbi.nlm.nih.gov/pubmed/27457238 http://dx.doi.org/10.1007/s11892-016-0772-0

Ejemplares similares

Management of Type 1 Diabetes in Pregnancy
por: Feldman, Anna Z., et al.
Publicado: (2016)

Advanced Technology in the Management of Diabetes: Which Comes First—Continuous Glucose Monitor or Insulin Pump?
por: Martin, Christopher T., et al.
Publicado: (2019)

HbA1c variability in adults with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) therapy compared to multiple daily injection (MDI) treatment
por: Scott, Emma S, et al.
Publicado: (2019)

Efficacy of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion (CSII) in Hospitalized Patients with Type 2 Diabetes
por: Lyu, Fu-ping, et al.
Publicado: (2020)

Insulin resistance relates to DKA severity and affects insulin requirement in children with type 1 diabetes at onset
por: Mastromauro, Concetta, et al.
Publicado: (2022)

Management of glycemic variation in diabetic patients receiving parenteral nutrition by continuous subcutaneous insulin infusion (CSII) therapy
por: Li, Feng-fei, et al.
Publicado: (2018)

Faster Insulin Aspart for Continuous Subcutaneous Insulin Infusion: Is It Worth It?
por: Rosinha, Patrícia, et al.
Publicado: (2022)

Economic evaluation of continuous subcutaneous insulin infusion for children with diabetes - a pilot study: CSII application for children – economic evaluation
por: Petkova, Elina, et al.
Publicado: (2013)

Effect of Health Information Technologies on Glycemic Control Among Patients with Type 2 Diabetes
por: Yoshida, Yilin, et al.
Publicado: (2018)

Comparison of continuous subcutaneous insulin infusion treatment and multiple daily injection treatment on the progression of diabetic complications in Japanese patients with juvenile‐onset type 1 diabetes mellitus
por: Masuda, Takafumi, et al.
Publicado: (2022)

Long-Term Effects of Initiating Continuous Subcutaneous Insulin Infusion (CSII) and Continuous Glucose Monitoring (CGM) in People with Type 1 Diabetes and Unsatisfactory Diabetes Control
por: Senn, Jon-Duri, et al.
Publicado: (2019)

Sensor-augmented CSII therapy with predictive low-glucose suspend following total pancreatectomy
por: Scott, E S, et al.
Publicado: (2017)

Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes
por: Lebovitz, Harold E.
Publicado: (2011)

Effects of potato resistant starch intake on insulin sensitivity, related metabolic markers and appetite ratings in men and women at risk for type 2 diabetes: a pilot cross‐over randomised controlled trial
por: Sanders, L. M., et al.
Publicado: (2020)

Development and validation of an instrument (CSII – Brazil) to assess users’ conceptual and procedural knowledge of continuous subcutaneous infusion systems
por: Amaral, Camilla Magalhães de Oliveira, et al.
Publicado: (2020)

Experiences and decision making during paediatric transitions to continuous sub-cutaneous insulin infusion (CSII): A mixed method study
por: Altmann, Erika, et al.
Publicado: (2018)

Pivotal Role of Timely Basal Insulin Replacement After Metformin Failure in Sustaining Long-Term Blood Glucose Control at a Target in Type 2 Diabetes
por: Bolli, Geremia B., et al.
Publicado: (2011)

Continuous Subcutaneous Insulin Infusion (CSII) Combined with Oral Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomized, Controlled Trials
por: Li, Hui, et al.
Publicado: (2022)

Carbohydrate Requirements for Prolonged, Fasted Exercise With and Without Basal Rate Reductions in Adults With Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion
por: McGaugh, Sarah M., et al.
Publicado: (2021)

Insulin Use Early in the Course of Type 2 Diabetes Mellitus: The ORIGIN Trial
por: Hanefeld, Markolf, et al.
Publicado: (2013)

Identification of infants with increased type 1 diabetes genetic risk for enrollment into Primary Prevention Trials—GPPAD‐02 study design and first results
por: Winkler, Christiane, et al.
Publicado: (2019)

Continuous Subcutaneous Insulin Infusion Therapy Resulting in Improved Glycemic Control in Patient With Low Health Literacy
por: Mandal, Shobha, et al.
Publicado: (2021)

Continuous subcutaneous insulin infusion: practical issues
por: Saboo, Banshi D., et al.
Publicado: (2012)

Management of adrenocortical insufficiency with continuous subcutaneous hydrocortisone infusion: long-term experience in three patients
por: Khanna, A, et al.
Publicado: (2015)

Subcutaneous fast-acting insulin analogues, alone or in combination with long-acting insulin, versus intravenous regular insulin infusion in patients with diabetic ketoacidosis: protocol for an updated systematic review and meta-analysis of randomised trials
por: Lim, Beng Leong, et al.
Publicado: (2023)

Type 1 Diabetes at a Crossroads!
por: Cefalu, William T., et al.
Publicado: (2015)

Mixed‐meal tolerance test to assess residual beta‐cell secretion: Beyond the area‐under‐curve of plasma C‐peptide concentration
por: Ruan, Yue, et al.
Publicado: (2019)

Increased tissue factor activity promotes thrombin generation at type 1 diabetes onset in children
por: Jasser‐Nitsche, Hildegard, et al.
Publicado: (2020)

Celiac disease can be predicted by high levels of tissue transglutaminase antibodies in children and adolescents with type 1 diabetes
por: Cerqueiro Bybrant, Mara, et al.
Publicado: (2020)

Extended family history of type 1 diabetes in HLA‐predisposed children with and without islet autoantibodies
por: Kuusela, Salla, et al.
Publicado: (2020)

Human plasma‐derived alpha(1)‐proteinase inhibitor in patients with new‐onset type 1 diabetes mellitus: A randomized, placebo‐controlled proof‐of‐concept study
por: Lagarde, William H., et al.
Publicado: (2020)

Viral infection‐related gene upregulation in monocytes in children with signs of β‐cell autoimmunity
por: Valta, Milla, et al.
Publicado: (2022)

Associations between deduced first islet specific autoantibody with sex, age at diagnosis and genetic risk factors in young children with type 1 diabetes
por: Ilonen, Jorma, et al.
Publicado: (2022)

Antibiotic treatment during early childhood and risk of type 1 diabetes in children: A national birth cohort study
por: Antvorskov, Julie Christine, et al.
Publicado: (2020)

HbA1c as a time predictive biomarker for an additional islet autoantibody and type 1 diabetes in seroconverted TEDDY children
por: Salami, Falastin, et al.
Publicado: (2022)

PSUN173 Factors determining insulin dose while transitioning from intravenous insulin infusion to subcutaneous insulin in patients with type 2 diabetes following cardiac bypass surgery.
por: Bansal, Beena, et al.
Publicado: (2022)

A Continuous Subcutaneous Insulin Infusion Needle Break
por: George, Minu M., et al.
Publicado: (2015)

Insulin Therapy for Type 2 Diabetes
por: Swinnen, Sanne G., et al.
Publicado: (2009)

Regular insulin, rather than rapid‐acting insulin, is a suitable choice for premeal bolus insulin in lean patients with type 2 diabetes mellitus
por: Kuroda, Akio, et al.
Publicado: (2013)

Basal Insulin Requirement Is ∼30% of the Total Daily Insulin Dose in Type 1 Diabetic Patients Who Use the Insulin Pump
por: Kuroda, Akio, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_qvsufjeou4nnvn76d3on72oq11